My take on the blog: 1. NASDAQ Listing: GC st
Post# of 30028
Posted On: 11/07/2015 1:44:06 PM
My take on the blog:
1. NASDAQ Listing: GC stated conditions in the market caused rapid deterioration. Management could not admit to any fault because that would open the door for lawsuits. Moreover, he is telegraphing that by reducing the burn rate to $500k/mo, there will not be a lot of dilution going forward. Here, the lack of any mention on the upcoming vote to increase OS to 150 mil is very interesting. Either he didn't want to irritate investors any further, or it is not a make or break outcome given the reduction in burn rate in addition to any revenues from the upcoming DX transaction. I think he held the blog until Friday to see how well the SP would hold up knowing major dilution is taking place.
2. Diagnostic Transaction: It doesn't sound like there will be an outright sale of the division or the components. They are still making plans for CLIA launch of MSPrecise & Lympro. The choices are to spin it out or more likely a partnership for the entire division ("remain on track to transact on the diagnostic division"
. If it is a partnership, they will not be getting much upfront cash because, they have refocused their business plant based on shortage of funds for the foreseeable future.
3. ESS & Eltoprazine: Like the DX, again they are not looking to sale the assets but to form partnerships with a possible spin-off ("ESS and Eltoprazine; each of these assets, individually, could provide a pipeline for a very valuable standalone public company"
I have enjoyed reading all the participants take on the blog. We are all in the same boat. Now that things are a little more clearer, I will consider adding more shares in the next few weeks once most of the dilution has subsided. GLTA
1. NASDAQ Listing: GC stated conditions in the market caused rapid deterioration. Management could not admit to any fault because that would open the door for lawsuits. Moreover, he is telegraphing that by reducing the burn rate to $500k/mo, there will not be a lot of dilution going forward. Here, the lack of any mention on the upcoming vote to increase OS to 150 mil is very interesting. Either he didn't want to irritate investors any further, or it is not a make or break outcome given the reduction in burn rate in addition to any revenues from the upcoming DX transaction. I think he held the blog until Friday to see how well the SP would hold up knowing major dilution is taking place.
2. Diagnostic Transaction: It doesn't sound like there will be an outright sale of the division or the components. They are still making plans for CLIA launch of MSPrecise & Lympro. The choices are to spin it out or more likely a partnership for the entire division ("remain on track to transact on the diagnostic division"
. If it is a partnership, they will not be getting much upfront cash because, they have refocused their business plant based on shortage of funds for the foreseeable future. 3. ESS & Eltoprazine: Like the DX, again they are not looking to sale the assets but to form partnerships with a possible spin-off ("ESS and Eltoprazine; each of these assets, individually, could provide a pipeline for a very valuable standalone public company"
I have enjoyed reading all the participants take on the blog. We are all in the same boat. Now that things are a little more clearer, I will consider adding more shares in the next few weeks once most of the dilution has subsided. GLTA
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼